Furthermore, one of the catechol-based ERCC1-XPF inhibitors (13 compounds) showed higher activity in NER and selectivity against deoxyribonuclease I and Flap structure-specific endonuclease 1 (FEN-1) in A375 melanoma cells, resulting in improved cisplatin activity.24 Here, ERCC4 is linked to melanoma.